click here.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Paris, France and Munich, Germany, June 4, 2018 – TRiCares SAS, a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the successful completion of a \u20ac22 Million ($25.4 Million) Series B financing round. Proceeds from the financing will be used to advance product development, to…<\/p>\n","protected":false},"author":5,"featured_media":2422,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-2424","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"\n
TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Paris, France and Munich, Germany, June 4, 2018 – TRiCares SAS, a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the successful completion of a \u20ac22 Million ($25.4 Million) Series B financing round. Proceeds from the financing will be used to advance product development, to...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-04T15:37:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-07T18:01:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1185\" \/>\n\t<meta property=\"og:image:height\" content=\"585\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Stagiaire Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Stagiaire Communication\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/\"},\"author\":{\"name\":\"Stagiaire Communication\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/c00e4b2e37dad5476a07678494c723e8\"},\"headline\":\"TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation\",\"datePublished\":\"2018-06-04T15:37:09+00:00\",\"dateModified\":\"2020-10-07T18:01:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/\"},\"wordCount\":87,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg\",\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/\",\"name\":\"TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg\",\"datePublished\":\"2018-06-04T15:37:09+00:00\",\"dateModified\":\"2020-10-07T18:01:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#primaryimage\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg\",\"width\":1185,\"height\":585},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/c00e4b2e37dad5476a07678494c723e8\",\"name\":\"Stagiaire Communication\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b8fc49c2885cc8bd47fc12d37bdc253b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b8fc49c2885cc8bd47fc12d37bdc253b?s=96&d=mm&r=g\",\"caption\":\"Stagiaire Communication\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/","og_locale":"en_US","og_type":"article","og_title":"TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation - ANDERA PARTNERS","og_description":"Paris, France and Munich, Germany, June 4, 2018 – TRiCares SAS, a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the successful completion of a \u20ac22 Million ($25.4 Million) Series B financing round. Proceeds from the financing will be used to advance product development, to...","og_url":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2018-06-04T15:37:09+00:00","article_modified_time":"2020-10-07T18:01:57+00:00","og_image":[{"width":1185,"height":585,"url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg","type":"image\/jpeg"}],"author":"Stagiaire Communication","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Stagiaire Communication"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/"},"author":{"name":"Stagiaire Communication","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/c00e4b2e37dad5476a07678494c723e8"},"headline":"TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation","datePublished":"2018-06-04T15:37:09+00:00","dateModified":"2020-10-07T18:01:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/"},"wordCount":87,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg","articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/","url":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/","name":"TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#primaryimage"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg","datePublished":"2018-06-04T15:37:09+00:00","dateModified":"2020-10-07T18:01:57+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#primaryimage","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg","width":1185,"height":585},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/tricares-closes-e22-million-25-4-million-series-b-financing-round-to-fund-development-of-minimally-invasive-treatment-of-tricuspid-regurgitation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"TRiCares Closes \u20ac22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/c00e4b2e37dad5476a07678494c723e8","name":"Stagiaire Communication","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b8fc49c2885cc8bd47fc12d37bdc253b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b8fc49c2885cc8bd47fc12d37bdc253b?s=96&d=mm&r=g","caption":"Stagiaire Communication"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/2424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=2424"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/2424\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media\/2422"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=2424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=2424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/06\/Tricares.jpg\")
Paris, France and Munich, Germany, June 4, 2018 – TRiCares SAS, a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the successful completion of a \u20ac22 Million ($25.4 Million) Series B financing round. Proceeds from the financing will be used to advance product development, to conduct clinical trials and to gain CE registration in Europe.<\/p>\n